Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation

• المؤلفون الرئيسيون: André B. P. van Kuilenburg (مؤلف), Carla E. M. Hollak (مؤلف), Ana Travella (مؤلف), Melisa Jacobs (مؤلف), Lucas D. Gentilini (مؤلف), René Leen (مؤلف), Karen M. M. Ghauharali-van der Vlugt (مؤلف), Femke S. Beers Stet (مؤلف), Susan M. I. Goorden (مؤلف), Sanne van der Veen (مؤلف), Marcelo Criscuolo (مؤلف), Mariana Papouchado (مؤلف)
• التنسيق: كتاب
• منشور في: Adis, Springer Healthcare, 2023-04-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Background and Objective Fabry disease (FD) is a rare lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (aGal A). Since 2001, two different enzyme replacement therapies have been authorized, with agalsidase beta being used in most parts of the Western world....